NASDAQ: SNTISenti Biosciences Inc Stock
$0.90-0.02 (-2.17%)
Updated Mar 23, 2026
SNTI Price
$0.90
Fair Value Price
N/A
Market Cap
$23.66M
52 Week Low
$0.80
52 Week High
$5.10
P/E
-0.27x
P/B
2.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$47.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.49
Operating Cash Flow
-$50M
Beta
1.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SNTI Overview
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNTI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SNTI
Ranked#447 of 469
Ranked#447 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.54 | A | |
| $16.01 | A | |
| $182.32 | A |
Be the first to know about important SNTI news, forecast changes, insider trades & much more!
SNTI News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNTI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SNTI is good value based on its book value relative to its share price (2.91x), compared to the US Biotechnology industry average (4.63x)
P/B vs Industry Valuation
SNTI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SNTI due diligence checks available for Premium users.
Valuation
SNTI fair value
Fair Value of SNTI stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$3.18
Undervalued by
71.74%
SNTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNTI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
26.93x
Market
31.38x
SNTI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.91x
Industry
4.63x
SNTI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNTI's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.1M
Profit Margin
0%
SNTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$52.7M
Liabilities
$44.6M
Debt to equity
5.49
SNTI's short-term assets ($18.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNTI's long-term liabilities ($32.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.4M
Investing
$0.0
Financing
$124.0k
SNTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNTI vs Biotech Stocks
Senti Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.